CD86 and neoplasm: FcγRI‐CAR‐HMs treatment shifted tumor‐associated macrophages (TAMs) from an immunosuppressive to immunostimulatory phenotype, evidenced by upregulated CD86/IL‐1β/IL‐12/TNF‐α and downregulated CD206/TGF‐β (Figure 5f,g; Figures S11a,b and S12, Supporting Information).